Advances in molecular biology now make it possible to detect diseases sooner, allowing physicians to advise patients on optimal therapies. “Global Molecular Diagnostics Market: Opportunities & Future Forecast” reports that based on its exceptional ability to accurately detect the primary cause of disease, molecular diagnostics has emerged as the fastest growing segment of the in vitro diagnostics (IVD) industry.
Alzheimer’s disease affects more than 26 million people worldwide. This number is expected to grow to more than 106 million in 2050. Its economic burden and impact on patient wellness and quality of life for both patients and their caregivers is crushing.
The core theory behind preventative medicine is almost psychic. To stop a disease from wielding its mighty weapons before it occurs is based on foreknowledge of a patient’s susceptibility to the illness.
According to the American Heart Association, more than 13 million people suffer from coronary heart disease, 6 million from angina, and 7 million from myocardial infraction. Rapid technological advances and product innovation are transforming the cardiology market.
At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.
The introduction of delivering a drug on film might be the best thing since sliced bread. Similar to breath enhancement strips, this edible film technology is in studies to be used for erectile dysfunction, migraine, insomnia, bipolar disorder, and pain management!
Unique to the human species is the ability to think, to reason logically, and to remember, in detail, events of the past. But the brain is fragile, and when disrupted, the loss of cognitive functioning—thinking, remembering, and reasoning—to such an extent that it interferes with a person’s daily life and activities poses a major concern.
On January 25th, 2011, at 8am at the Apple Store on Fifth Ave, Dr. Ali Sadrieh, a Beverly Hills-based surgeon gave an amazing presentation on the effectiveness of the paperless system as he applies it in his office. He lead the discussion into the new ingenious software Mac Practice MD 4.1 and hardward provided by Apple to help the doctors of today run a more effective practice.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Day 2 at the OneMed Forum highlighted a series of exciting presentations & networking opportunities.
Copyright © 2025 | WordPress Theme by MH Themes